Edunn wins $100,000 grant from Alzheimer’s Drug Discovery Foundation

Edunn’s lead drug candidate, EDN-OL1, is an oligonucleotide-based drug that has shown promise in halting and reversing the progression of Alzheimer’s disease (AD) in animal models. EDN-OLI reduces the production of amyloid beta proteins found in the brain and believed to cause AD.

Thomas Darling, president and CEO of Edunn, said: “The grant will support research to further confirm that EDN-OL1 reduces amyloid in the brain. These data will be included in submissions to the FDA and regulatory agencies as we continue the preclinical development of EDN-OL1 for the treatment and prevention of AD and Down syndrome.”